Company news
Rani Therapeutics Holdings, Inc. news in 2025
Rani Therapeutics Holdings, Inc.'s news releases, calls and decks from 2025, newest first.
Rani Therapeutics to Participate in the Evercore Healthcare Conference
November 24, 2025
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
November 6, 2025
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
October 30, 2025
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
October 23, 2025
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
October 23, 2025
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
October 17, 2025
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
October 17, 2025
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
August 7, 2025
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
July 15, 2025
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
July 14, 2025
Rani Therapeutics Announces Research Agreement with Chugai
May 19, 2025
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
May 13, 2025
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
March 31, 2025
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
March 26, 2025
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
March 25, 2025
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
February 4, 2025